Skip to content
10-Q

Quarterly Report

GeoVax Labs, Inc. GOVX

0001437749-26-017048

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 14, 2026 3.47M sh
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $16.89K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$3.54M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$5.97M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $1.27M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $3.09M
Stockholders Equity Q1 2026 · Mar 31, 2026 $493.77K
Stockholders Equity Q1 2026 · Dec 31, 2025 $3.83M
Stockholders Equity Q1 2026 · Mar 31, 2025 $7.9M
Stockholders Equity Q1 2026 · Dec 31, 2024 $5.05M
Current Liabilities Q1 2026 · Mar 31, 2026 $2.29M
Current Liabilities Q1 2026 · Dec 31, 2025 $1.94M
Total Liabilities Q1 2026 · Mar 31, 2026 $2.49M
Total Liabilities Q1 2026 · Dec 31, 2025 $2.52M
Current Assets Q1 2026 · Mar 31, 2026 $2.43M
Current Assets Q1 2026 · Dec 31, 2025 $5.31M
Total Assets Q1 2026 · Mar 31, 2026 $2.98M
Total Assets Q1 2026 · Dec 31, 2025 $6.34M
Eps Basic Q1 2026 · Mar 31, 2026 −$2.62
Eps Basic restated Q1 2026 · Mar 31, 2025 −$11.20
Sga Expense Q1 2026 · Mar 31, 2026 $1.37M
Sga Expense Q1 2026 · Mar 31, 2025 $1.69M
Rd Expense Q1 2026 · Mar 31, 2026 $3.9M
Rd Expense Q1 2026 · Mar 31, 2025 $5.35M
Net Income Q1 2026 · Mar 31, 2026 −$5.26M
Net Income Q1 2026 · Mar 31, 2025 −$5.36M
Operating Income Q1 2026 · Mar 31, 2026 −$5.27M
Operating Income Q1 2026 · Mar 31, 2025 −$5.41M
Revenue Q1 2026 · Mar 31, 2026 $0
Revenue Q1 2026 · Mar 31, 2025 $1.64M